Josep Llovet

Josep Llovet co-developed the Barcelona Clinic Liver Cancer (BCLC) staging system and treatment algorithm that became the global standard for HCC management, and led the SHARP trial that established sorafenib as the first approved systemic therapy for advanced HCC in 2007. His laboratory has characterized the molecular landscape and oncogenic drivers of HCC, and he has contributed to understanding mechanisms of sorafenib resistance and the rationale for immune checkpoint combinations. He chairs the EASL HCC guideline committee and is the most-cited liver cancer investigator in the world.